IP Verse

Modulation Of Ube3A-Ats Expression

Patent No. EP3770258 (titled "Modulation Of Ube3A-Ats Expression") was filed by Baylor College OF Medicine on Jun 25, 2013. The application was issued on Jul 17, 2024.

Patent Summary

Targeting UBE3A antisense transcript (ATS) to induce paternal expression of UBE3A in cells and animals. The approach involves contacting cells with antisense compounds that specifically target the UBE3A-ATS region, which is located upstream of the UBE3A mRNA and downstream of the UBE3A-ATS sequence. This region is complementary to the 3' end of UBE3A pre-mRNA. By targeting this region, the antisense compounds effectively disrupt UBE3A-ATS expression without affecting neighboring small nucleolar RNAs (snoRNAs). This approach enables the induction of paternal UBE3A expression without compromising the levels of neighboring snoRNAs.

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
CMS CAMERON MCKENNA NABARRO OLSWANGApr 16, 2025CMS CAMERON MCKENNA NABARRO OLSWANG
HGFApr 16, 2025HGF
STRAWMANApr 10, 2025KELTIE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3770258

BAYLOR COLLEGE OF MEDICINE
Application Number
EP20182895A
Filing Date
Jun 25, 2013
Status
Granted And Under Opposition
Jun 14, 2024
Publication Date
Jul 17, 2024
External Links
Slate, Register , Google Patents